_arjun-vasant-balar-md-on-urothelial-carcinoma-analysis-of-the-imvigor210-cohort-1.jpg "Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1 from balar Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 33 sec
✓ Published: 06-Jun-2016
✓ Published: 06-Jun-2016
Description:
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_qasm-hawrami-balar.webp "Kurdmax Music")
_shanaz-zahir-balar-w-balar-124.webp "Kurdmax Media Network")
_arjun-v-balar-md-on-urothelial-cancer-results-from-keynote-052.webp "Arjun V. Balar, MD, of the NYU Perlmutter Cancer Center, discusses preliminary phase II study findings on pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer. (Abstract LBA32)")
_shubh-baller-official-music-video.webp "SHUBH")
_qasm-hawrami-balar.jpg)
_shanaz-zahir-balar-w-balar-124.jpg)
_arjun-v-balar-md-on-urothelial-cancer-results-from-keynote-052.jpg)
_shubh-baller-official-music-video.jpg)
![[+]](/images/menu.gif){kind=small}